Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

Launched by CHRISTOPHER KAI SHUN LEUNG · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether certain supplements can help improve vision in adults with glaucoma, a condition that affects the eye and can lead to vision loss. The researchers want to find out if taking different forms of a substance called NAD (which is important for energy and cell health) can make a difference in how well glaucoma patients can see. Participants will be randomly assigned to take one of four different NAD supplements or a placebo (a non-active substance) every day for two weeks. They will undergo eye exams and provide blood samples before and after the study to see if these supplements improve their visual function and how they affect the levels of NAD in the blood.

To be eligible for this study, participants need to be at least 18 years old and have a diagnosis of glaucoma with specific vision and eye pressure requirements. They should not have other eye diseases or conditions that could interfere with the results. Throughout the study, their safety will be monitored closely. This research aims to understand whether boosting NAD levels can help improve vision in glaucoma patients and what changes occur in their blood during the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • glaucoma patients
• • age ≥ 18 years
• • best corrected VA ≥20/40
• • IOP \<21 mmHg
• • visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard
• Exclusion Criteria:
• • pathological myopia
• • diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
• • inability to perform reliable visual field
• • suboptimal quality of OCT images
• • diabetic retinopathy/maculopathy
• • history of abnormal liver function within 12 months
• • known allergy to NAD precursor supplement(s)
• • pregnancy or lactation
• • use of NAD precursor supplements 14 days prior to baseline.